MedTrace Logo

Prospective Clinicogenomic Program

NCT04180176 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 945

Last updated 2024-01-17

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small-Cell Lung Cancer (SCLC)

Interventions

OTHER

Blood Draw

Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.

Sponsors & Collaborators

  • Flatiron Health, Inc.; Foundation Medicine, Inc.

    collaborator UNKNOWN

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04180176 on ClinicalTrials.gov